Coya Therapeutics
Business Services · Texas, United States · <25 Employees
View Company Info for Free
About
Headquarters
5850 San Felipe St Ste 500, Houston, Texas, 770...Phone Number
(800) 587-8170Website
www.coyatherapeutics.comRevenue
$6.1 MillionStock Symbol
COYAIndustry
Most Recent Scoops
Highlights
$25.3M
Total Funding Amount
$5M
Most Recent Funding Amount
3
Number of Funding Rounds
Who is Coya Therapeutics
Coya Therapeutics Org Chart
Is Coya Therapeutics your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Coya Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Coya Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Coya Therapeutics
Product Launch: Get notified when Coya Therapeutics launches new products
Check if Coya Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Coya Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Coya Therapeutics has new funding data
Check out if Coya Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Coya Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Coya Therapeutics
Compare insights from companies similar to Coya Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Coya Therapeutics financials insights
Gather financial insights about Coya Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Coya Therapeutics Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Coya Therapeutics Tech Stack
A closer look at the technologies used by Coya Therapeutics
Most Recent Scoops
Coya Therapeutics News & Media
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital. ToplinCoya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 – 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL. On Tuesday, December 3 at 12:55Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan. Dear Fellow Stockholder, Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose bCoya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024. Recent Corporate Highlights Announced positive results from an investigator initiated double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer’s
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Coya Therapeutics
Headquartered in Houston, TX, Coya Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease. The company's CTreg (Cryopreservation for Tregs) system is patent pending and the first in the industry to overcome prior limitations of Tre... Read More